

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
8 July 2004 (08.07.2004)

PCT

(10) International Publication Number
WO 2004/056355 A1

(51) International Patent Classification⁷: **A61K 31/19**, C07C 53/134, 327/16, A61P 3/06, 3/08, 3/10

(21) International Application Number:

PCT/IT2003/000820

(22) International Filing Date:

16 December 2003 (16.12.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

RM2002A000629

19 December 2002 (19.12.2002) IT

(71) Applicant (for all designated States except US): SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.p.A. [IT/IT]; Viale Shakespeare, 47, I-00144 Rome (IT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): GIANNESI, Fabio [IT/IT]; c/o Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., A., Via Pontina Km. 30, 400, I-00040 Pomezia (IT). TASSONI, Emanuela [IT/IT]; c/o Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., A., Via Pontina Km. 30, 400, I-00040 Pomezia (IT). TINTI, Maria, Ornella [IT/IT]; c/o Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Via Pontina, km 30,400, I-00040 Pomezia (IT). PESSOTTO, Pompeo [IT/IT]; c/o Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Via Pontina, Km. 30, 400, I-00040 Pomezia (IT). DELL'UOMO, Natalina [IT/IT]; c/o Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Via Pontina, Km 30,400, I-00040 Pomezia (IT). SCIARRONI, Anna, Floriana [IT/IT]; c/o Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Via Pontina, Km. 30, 400, I-00040 Pomezia (IT). BRUNETTI, Tiziana [IT/IT]; c/o Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Via Pontina, Km. 30,400, I-00040 Pomezia (IT). MILAZZO, Ferdinando, Maria [IT/IT]; c/o Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Via Pontina, Km. 30,400, I-00040 Pomezia (IT).

(74) Agent: CAMPANELLI, Domenico; c/o Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Via Pontina, km 30,400, I-00040 Pomezia (IT).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designation US


— of inventorship (Rule 4.17(iv)) for US only

Published:

— with international search report

[Continued on next page]

(54) Title: USE OF α -PHENYLTHIOCARBOXYLIC AND α -PHENYLOXYCARBOXYLIC ACIDS WITH SERUM-GLUCOSE-LOWERING AND SERUM-LIPID-LOWERING ACTIVITY



(57) Abstract: The use is described of derivatives of α -phenylthiocarboxylic and α -phenyloxycarboxylic acids with formula (I): in which the substituents have the meanings described in the text, for the preparation of a medicine for the prophylaxis and treatment of diabetes, particularly type 2 diabetes, its complications, the various forms of insulin resistance, and hyperlipidaemias.



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.